The global Nipah virus (NiV) infection testing market is expected to garner a market value of USD 1,974.17 million in 2023 and is expected to accumulate a market value of USD 3,277.49 million by registering a CAGR of 5.2% in the forecast period 2023 to 2033.
Growth of the Nipah virus (NiV) infection testing market can be attributed to the need for early detection and control of outbreaks of Nipah virus infection. The market for Nipah virus (NiV) infection testing registered a CAGR of 3.1% in the historical period 2018 to 2022
Nipah virus (NiV) infection testing refers to the various methods used to detect the presence of the Nipah virus in a person's blood, saliva, or other bodily fluids. Nipah virus is a zoonotic virus, which means it is transmitted from animals to humans. The virus was first identified in Malaysia in 1999, and since then, it has caused several outbreaks in South and Southeast Asia, including India, Bangladesh, and Malaysia. The Nipah virus infection testing includes serological tests, molecular tests and virus isolation.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1,974.17 million |
| Anticipated Forecast Value (2033) | USD 3,277.49 million |
| Projected Growth Rate (2023 to 2033) | 5.2% CAGR |
Explore FMI!
Book a free demo
According to market research and competitive intelligence provider Future Market Insights- the market for Nipah virus (NiV) infection testing reflected a value of 3.1% during the historical period, 2018 to 2022.
The market growth has been driven by factors such as increased awareness about the disease, rising investments in R&D activities for developing advanced diagnostic tests, and increasing government initiatives to control the spread of Nipah virus infection.
However, the outbreak of the COVID-19 pandemic has affected the Nipah virus testing market to some extent, as the focus of the healthcare industry shifted towards managing the pandemic. The pandemic has also resulted in disruptions in the supply chain, which has affected the production and distribution of diagnostic tests for Nipah virus infection. Thus, the market for Nipah virus (NiV) infection testing is expected to register a CAGR of 5.2% in the forecast period 2023 to 2033.
Investment in research and development boosting testing technologies for Nipah virus
The growing awareness of Nipah virus and its potential to cause severe illness has led to an increased demand for NiV infection testing. As people become more aware of the disease, they are more likely to seek testing if they experience symptoms.
The development of advanced diagnostic technologies, such as PCR and ELISA, has improved the accuracy and speed of NiV infection testing. These advancements have increased the demand for NiV infection testing and are expected to drive the growth of the market in the coming years.
Governments in affected regions are taking steps to prevent and control Nipah virus outbreaks. This includes increasing funding for research into NiV infection testing and improving access to testing for people in affected areas.
Private companies are investing in research and development of NiV infection testing methods and technologies. This has led to the development of new and improved testing methods, which are expected to drive the growth of the market in the coming years.
Technological advancements in testing spurring Nipah virus testing market growth
The symptoms of NiV infection can range from mild flu-like symptoms to severe respiratory illness or encephalitis. The severity of the disease can vary depending on the individual and the strain of the virus. NiV infection can be fatal in some cases, making early diagnosis and treatment critical.
Inaccessibility to testing and lack of awareness affecting market growth
Many regions affected by Nipah virus outbreaks, access to NiV infection testing is limited. This is particularly true in rural areas, where healthcare infrastructure may be limited. Improving access to testing is a challenge that the NiV infection testing market is facing. Despite growing awareness of Nipah virus, many people in affected regions are still not aware of the disease or the importance of testing. This can lead to delays in diagnosis and treatment, and may hinder the growth of the NiV infection testing market.
While there are supportive treatments available for Nipah virus, there is no specific treatment for the disease. This limits the ability of the NiV infection testing market to offer specific treatment options and may make it more challenging to convince people to undergo testing. The cost of NiV infection testing can be high, particularly for advanced diagnostic methods like PCR. This can make testing inaccessible to many people, particularly in low- and middle-income countries.
The Nipah virus is highly variable, with different strains causing different symptoms and exhibiting different levels of virulence. This variability can make it challenging to develop accurate diagnostic tests that can detect all strains of the virus. This, in turn, causes delays in understanding the effect of the virus and controlling the same takes longer durations. All these factors are affecting the growth of Nipah virus (NiV) infection testing market.
Government initiatives contributing to Nipah virus infection testing in the regions
The East Asian and South Asian Nipah virus (NiV) infection testing markets are among the largest and fastest-growing markets globally. The market is driven by factors such as the high incidence of Nipah virus outbreaks in the region, increasing government initiatives to control the spread of the virus, and rising investments in R&D activities to develop advanced diagnostic tests.
The growth of the market in the region can be attributed to the high incidence of Nipah virus outbreaks in countries such as India, Bangladesh, and Malaysia, which has led to an increased demand for diagnostic tests for early detection and control of the disease. Additionally, the rising awareness about the disease among healthcare professionals and the general public has further boosted the demand for Nipah virus testing in the region.
The Asia Pacific Nipah virus testing market is also witnessing an increasing trend of collaboration between government agencies, healthcare organizations, and research institutions to develop more accurate and efficient diagnostic tests for the virus. For instance, in 2021, the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) announced the development of a rapid diagnostic test for Nipah virus, which is expected to aid in the early detection and control of the disease in the country. Collectively, both regions are expected to possess 45% market share for Nipah virus (NiV) infection testing market in 2023.
Investment in research and development activities propelling demand for Nipah virus testing
The Middle East and Africa (MEA) Nipah virus (NiV) infection testing market is a small but growing market. The market is driven by factors such as the rising incidence of Nipah virus outbreaks in the region and increasing awareness about the disease among healthcare professionals and the general public.
The Middle East region has reported several outbreaks of Nipah virus in recent years, with the largest outbreak reported in the United Arab Emirates (UAE) in 2018. The outbreak resulted in the culling of thousands of camels, which were found to be the primary source of the virus in the region.
The market growth in the MEA region is also being driven by increasing government initiatives to control the spread of Nipah virus and rising investments in R&D activities to develop more accurate and efficient diagnostic tests. For instance, in 2021, the Dubai Municipality launched a new PCR-based diagnostic test for the detection of Nipah virus, which is expected to aid in the early detection and control of the disease in the UAE. Thus, Middle East and Africa is expected to possess 39% market share for Nipah virus (NiV) infection testing market in 2023.
Availability of medication and patient care services increasing dependency on hospitals for NiV infection testing
Hospitals are the best option for testing for Nipah virus (NiV) infection owing to their access to the most advanced diagnostic methods. Additionally, hospitals are staffed with highly trained healthcare professionals who specialize in diagnosing illnesses like NiV and have the necessary resources to handle any situation.
Hospitals are also able to provide additional patient care services such as providing medications or monitoring vital signs, while also ensuring the safety of other patients and healthcare workers. As a result, hospitals are the safest and most reliable option for testing and treating NiV infection. Thus, hospitals are expected to possess 40% market share for Nipah virus (NiV) infection testing market in 2023.
Key players in the Nipah virus (NiV) infection testing market are Aurobindo, Minapharm, Roche, Lupin Ltd, Siegfried, Vivacure, Starlake Bioscience, Xaretto, Liferiver, MyBioSource, Krishgen Biosystems
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1,974.17 million |
| Market Value in 2033 | USD 3,277.49 million |
| Growth Rate | CAGR of 5.2% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Test Type, End User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Austria, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Aurobindo Pharma; Minapharm; Roche Diagnostics; Lupin Ltd.; Siegfried; Vivacure; Starlake Bioscience; Xaretto; Liferiver; MyBioSource; Krishgen Biosystems |
| Customization | Available Upon Request |
The market is valued at USD 1.9 billion in 2023.
Aurobindo, Minapharm, Roche, and Lupin Ltd, are the key market players.
The market is expected to reach USD 3.2 billion by 2033.
Investment in research and development drives the market prospects.
Both regions are likely to generate a share of 45.0% in 2023.
Home Respiratory Therapy Market – Growth & Forecast 2025 to 2035
Digital Telepathology Market is segmented by Application and End User from 2025 to 2035
Generalized Myasthenia Gravis Management Market - Growth & Treatment Advances 2025 to 2035
Hutchinson-Gilford Progeria Syndrome Market Growth – Innovations & Therapies 2025 to 2035
Home Infusion Therapy Devices Market - Growth & Forecast 2025 to 2035
Human Combinatorial Antibody Libraries (HuCAL) Market - Trends & Forecast 2025 to 2035
Nipah Virus (NiV) Infection Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
